CompaniesProgen Pharmaceuticals

Progen Pharmaceuticals

defunct
About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (7)
View all

Total Trials

7

As Lead Sponsor

6

As Collaborator

1

Total Enrollment

952

By Phase

PHASE3: 1PHASE1: 4PHASE2: 2

By Status

COMPLETED: 5TERMINATED: 2
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
NCT00705653
NCT00293488
NCT00705874
Hover over trial bars to see details

Recent Trials

NCT00568308Lead Sponsor
Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma
PHASE3Terminated
600 participants
Started: Dec 31, 2007 · Completed: Jul 31, 2008
NCT00446654Lead Sponsor
Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD
PHASE1Completed
43 participants
Started: Apr 30, 2007 · Completed: Oct 31, 2007
NCT00585416Collaborator
Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer
PHASE2Terminated
23 participants
Started: Jun 30, 2006 · Completed: Mar 31, 2009
NCT00705874Lead Sponsor
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
PHASE1Completed
172 participants
Started: May 31, 2006 · Completed: Sep 30, 2011
NCT00293488Lead Sponsor
SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma
PHASE1Completed
20 participants
Started: Jan 31, 2006
View all 7 trials →
Related Companies
Tbg Diagnostics
acquired